Canis ISSN: 2398-2942

Enrofloxacin

Contributor(s): Linda Horspool

Introduction

Name

  • Enrofloxacin.

Class of drug

  • Antibiotic.
  • Antimicrobial.
  • Fluoroquinolone.

Description

Chemical name

  • 1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.

Molecular formula

  • C19H22FN3O3.

Storage requirements

  • <30°C.
  • In a dry environment.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Other infections

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Antibiotics

  • Combination with chloramphenicol, macrolide antibiotics or tetracyclines may produce antagonistic effects.

Adsorbents and antacids containing cations (Mg, Al)

Sucralfate and zinc salts
  • May inhibit absorption; separate doses of these drugs by 6-8 hours.
Theophylline
  • Increases plasma theophylline levels Theophylline (in humans) - monitor carefully.

NSAIDs (non-steroidal anti-inflammatory drugs)

  • Potential pharmacodynamic interactions in the CNS could lead to seizures (in susceptible animals).
Probenecid
  • Blocks the tubular secretion of fluoroquinolones and may increase circulating concentrations and half-life.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromPubMed.
  • Blondeau JM, Borsos S, Blondeau LD, Blondeau BJ. (2012)In vitrokilling ofEscherichia coli,Staphylococcus pseudintermediusandPseudomonas aeruginosaby enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat.Vet Microbiol155(2-4), 284-290PubMed.
  • Shaheen B W, Boothe D M, Oyarzabal O A, Wang C, Johnson C M (2011)Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenicEscherichia coliisolates from dogs and cats.Am J Vet Res72(1), 25-32PubMed.

Other sources of information

  • Based onSmall Animal Formulary. Ed. I Ramsey (2010) 6th edn. Cheltenham: BSAVA. ISBN: 978 1 905319 11 4.
  • First International Veterinary Symposium on Baytril Proceedings 1992.
  • Second International Veterinary Symposium on Baytril Proceedings 1993.
  • Fourth International Veterinary Symposium on Baytril Proceedings 2009.

ADDED